Great things were expected of Allogene Therapeutics’ IPO this week – the company is led by Arie Belldegrun and David Chang, who masterminded development and approval of Kite Pharma’s CAR-T ...

Q3 2024 Earnings Call Transcript November 7, 2024 Allogene Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

David Chang, President and Chief Executive Officer ... to place undue reliance on these forward-looking statements, and Allogene disclaims any obligation to update these statements.

and the first CD19/CD70 dual CAR T candidate specifically designed for autoimmune disease,” said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene.

Detailed price information for Allogene Therapeutics Inc (ALLO-Q) from The Globe and Mail including charting and trades.

and the first CD19/CD70 dual CAR T candidate specifically designed for autoimmune disease,” said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene.

said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene. “We believe these efforts have the potential to redefine treatment paradigms, tailoring therapies to meet ...

and the first CD19/CD70 dual CAR T candidate specifically designed for autoimmune disease,” said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene. "We believe ...